Investigating Biomarkers for Alzheimer's Disease and Memory Loss
This observational study, Bio-Hermes-002, is creating a database to better understand Alzheimer's disease and memory loss. Researchers are collecting blood samples and brain PET scans (using Flortaucipir or investigational MK6240) from people aged 60 to 90 who are cognitively normal, have mild cognitive impairment, or mild-to-moderate Alzheimer's dementia. The goal is to see how well markers in your blood predict the presence of amyloid and tau proteins in your brain, which are linked to Alzheimer's. The study aims to enroll 1200 participants and will track these biomarkers and PET scan results over an average of 3 years to see if there's a meaningful relationship.
- Study design
- This is an observational study with a planned enrollment of 1200 participants. It is a cross-sectional study, meaning data is collected at a single point in time.
- What's involved
- You would provide a blood sample and have a PET scan of your brain. The study lasts for 120 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Biomarkers and PET will be measured through study completion, an average of 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
At a glance
Conditions
Where it's being run
26 sites across 12 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Biomarkers and PETThrough study completion, an average of 3 years
Measure blood biomarkers (Aβ 42/40, p-tau 181, p-tau 217, p-tau 231, total tau, and NFL) to see if it will predict the extent of tau and amyloid brain pathology as measured by PET brain imaging in participants shown to be cognitively normal (CN), have mild cognitive impairment (MCI), or have mild-to-moderate AD dementia.